# OnCo record dendreon (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/dendreon/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "dendreon" ;
  schema:name "Dendreon"@en ;
  schema:alternateName "Dendreon Pharmaceuticals"@en, "Dendreon Corporation"@en ;
  schema:description "Dendreon makes sipuleucel-T (Provenge), the first autologous cellular immunotherapy approved for cancer, for metastatic prostate cancer; the company went bankrupt in 2014 and has been owned by China's Sanpower group since 2017."@en ;
  schema:url <https://onco.cc/companies/dendreon/>, <https://www.dendreon.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Dendreon> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5256667> ;
  schema:citation <https://www.dendreon.com>, <https://clinicaltrials.gov/search?lead=Dendreon>, <https://en.wikipedia.org/wiki/Dendreon> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/sipuleucel-t/> ;
  onco:trials <https://onco.cc/trials/nct06134232/> .